Vetter Pharma said it held a successful open house Friday to members of the pharmaceutical industry and related officials following the opening of its Korean branch in November.
Vetter Pharma, which is a global contract manufacturing organization (CMO) specializing in prefilled syringes, presented its service portfolio and growth strategy for the Asia-Pacific region and Korea at the open house, it said.
“We are well aware that being physically close to our customers and their ongoing projects are the keys to good client relationships,” Managing Director Peter Soelkner said.
Another Vetter official agreed. “Our event today acts as an additional signal of our strategy to build on our local presence and activities in this market,” said Oskar Gold, Vetter’s senior vice president of key account management, market and corporate communications and customer project management.
The branch office aims to support existing business in Korea while creating new local and global customers seeking to meet development, manufacturing and packaging requirements for injectable drugs, it said.
In attendance were various business associates, including a Celltrion official who noted how the Korean biopharmaceutical sector benefits from Vetter Pharma services.
“Vetter can support us in competing on a level playing field and achieving our goals on a global scale,” said Javier Camposano, Celltrion’s managing director for drug product. “Companies operating in Korea, including ours, are in need of the services Vetter offers to bring our innovative products to local and global markets.”
The company said that it expects steady growth in this country with the branch opening as government policies are encouraging R&D investment to create innovative healthcare products to meet the demand for injectable medicines among a rapidly aging population.
<© Korea Biomedical Review, All rights reserved.>